T1	Participants 455 658	1692 patients who were refractory to or intolerant of their latest chemotherapy regimen were randomly assigned in a ratio of two to one either gefitinib (250 mg/day) or placebo, plus best supportive care
T2	Participants 942 995	1129 patients were assigned gefitinib and 563 placebo
